5th most common cancer in europe and 6th most comon in the US
430,000 new bladder cancer cases diagnosed in 2012 worldwide
3 times more common in men compared to women
highest lifetime treatment costs per patient out of all cancers
Bladder EpiCheck is Nucleix’s first product that includes a panel of 15 DNA methylation biomarkers for detection of bladder cancer.
Bladder EpiCheck is CE Marked and available in the EU, followed by other markets.
Bladder EpiCheck – Performance
EpiCheck has a very high ability to correctly identify patients with cancer
EpiCheck has a very high ability to correctly identify patients without cancer
EpiCheck negative predictive value means 99% probability of being a true negative
* Results are based on a European multi-center clinical study with 353 bladder cancer patients post-treatment that came for recurrence monitoring. Performed in leading urology centers in The Netherlands, Germany, Spain and Israel